Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amin Rahemtulla

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Blood|April 12, 2003
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic indexEvangelos Terpos, Richard Szydlo, Jane F Apperley, et al.
European Journal of Haematology|September 30, 2005
Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myelomaEvangelos Terpos, Katayoun Rezvani, Supratik Basu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 8, 2005
Human invariant NKT cells are required for effective in vitro alloresponsesScott Patterson, Ioannis Kotsianidis, Antonio Almeida, et al.
European Journal of Haematology|March 13, 2003
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myelomaEvangelos Terpos, Nora Viniou, Josu de la Fuente, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 14, 2011
Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation RegistryGordon Cook, Effie Liakopoulou, Rachel Pearce, et al.
Hematological Oncology|July 17, 2010
LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centreJiří Pavlů, Holger W Auner, Sarah Ellis, et al.
Leukemia & Lymphoma|February 8, 2013
Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantationHolger W Auner, Richard Szydlo, Alero Rone, et al.
British Journal of Haematology|November 17, 2006
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myelomaEvangelos Terpos, Deborah J Heath, Amin Rahemtulla, et al.
Biochimica Et Biophysica Acta|September 7, 2014
Nuclear proteasomes carry a constitutive posttranslational modification which derails SDS-PAGE (but not CTAB-PAGE)David S Pitcher, Kate de Mattos-Shipley, Ziming Wang, et al.
British Journal of Haematology|November 5, 2011
Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare systemHolger W Auner, Jiri Pavlu, Richard Szydlo, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Blood|April 12, 2003
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic indexEvangelos Terpos, Richard Szydlo, Jane F Apperley, et al.
European Journal of Haematology|September 30, 2005
Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myelomaEvangelos Terpos, Katayoun Rezvani, Supratik Basu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 8, 2005
Human invariant NKT cells are required for effective in vitro alloresponsesScott Patterson, Ioannis Kotsianidis, Antonio Almeida, et al.
European Journal of Haematology|March 13, 2003
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myelomaEvangelos Terpos, Nora Viniou, Josu de la Fuente, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 14, 2011
Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation RegistryGordon Cook, Effie Liakopoulou, Rachel Pearce, et al.
Hematological Oncology|July 17, 2010
LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centreJiří Pavlů, Holger W Auner, Sarah Ellis, et al.
Leukemia & Lymphoma|February 8, 2013
Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantationHolger W Auner, Richard Szydlo, Alero Rone, et al.
British Journal of Haematology|November 17, 2006
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myelomaEvangelos Terpos, Deborah J Heath, Amin Rahemtulla, et al.
Biochimica Et Biophysica Acta|September 7, 2014
Nuclear proteasomes carry a constitutive posttranslational modification which derails SDS-PAGE (but not CTAB-PAGE)David S Pitcher, Kate de Mattos-Shipley, Ziming Wang, et al.
British Journal of Haematology|November 5, 2011
Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare systemHolger W Auner, Jiri Pavlu, Richard Szydlo, et al.
Pageof 6